COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05715918

Not reported

Not reported

2023-02-08

Not recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria: volunteers must meet the following inclusion criteria: type of participants • healthy volunteers. age at the time of signing the informed consent • from 12 to 17 years inclusive (12 years 0 months 0 days - 17 years 11 months 30 days). paul • male or female. reproductive characteristics for girls with a history of mensis - a negative pregnancy test and consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). girls should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). for young men capable of conception - consent to adhere to adequate methods of contraception (use of contraceptives within a month after the second vaccination). young men and their sexual partners should use methods of contraception with a reliability of more than 90% (cervical caps with spermicide, diaphragms with spermicide, condoms, intrauterine spirals). research procedures written informed consent of a volunteer (14 years and older) and one of the parents to participate in a clinical trial. volunteers who are able to fulfill protocol requirements (i.e. answer phone calls, fill out a self-observation diary, come to control visits). non-inclusion criteria: volunteers cannot be included in the study if any of the following criteria are present: sars-cov-2 infection a case of established covid-19 disease confirmed by pcr and/or elisa in the last 6 months. history of contacts with confirmed or suspected cases of sars-cov-2 infection within 14 days prior to vaccination. positive igm or igg to sars-cov-2 detected on screening. positive pcr test for sars-cov-2 at screening / before vaccination. diseases or medical conditions serious post-vaccination reaction (temperature above 40 c, hyperemia or edema more than 8 cm in diameter) or complication (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions, accompanied or not accompanied by a feverish state) to any previous vaccination. burdened allergic history (anaphylactic shock, quincke's edema, polymorphic exudative eczema, serum sickness in the anamnesis, hypersensitivity or allergic reactions to the introduction of any vaccines in the anamnesis, known allergic reactions to vaccine components, etc.). guillain-barre syndrome (acute polyradiculitis) in the anamnesis. the axillary temperature at the time of vaccination is more than 37.0 ° c. positive blood test for hiv, syphilis, hepatitis b/c. acute infectious diseases (recovery earl

- • withdrawal of informed consent by a volunteer and/or a parent of a volunteer; the volunteer was included in violation of the inclusion/non-inclusion criteria of the protocol; availability of inclusion/non-inclusion criteria before vaccination; any condition of a volunteer that requires, in the reasoned opinion of a medical researcher, the withdrawal of a volunteer from the study; the established fact of pregnancy before the second vaccination; taking unauthorized medications (see section 6.2); the volunteer's incompetence with the study procedures; the volunteer refuses to cooperate or is undisciplined (for example, failure to attend a scheduled visit without warning the researcher and/or loss of communication with the volunteer), or dropped out of observation; for administrative reasons (termination of the study by the sponsor or regulatory authorities), as well as in case of gross violations of the protocol that may affect the results of the study.

2

Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products

12

17

Russia

Healthy volunteers

N/A

300

Geometric mean titer (GMT);Geometric mean titer (GMT);The level of seroconversion

None

Phase 3

[{"arm_notes": "", "treatment_id": 348, "treatment_name": "Covivac", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]